John Duncan Higgons
CIK 1581954 · Chief Operating Officer · last filed 2022-06-28
John Duncan Higgons is a Chief Operating Officer who has filed 46 SEC Form 4 insider transactions across 2 companies since 2014. The most recent filing, for JNCE, was dated Jun 28, 2022. Across all open-market trades the lifetime net is −$21.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $3.6M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$3.56M
2
46
-$21.37M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Jounce Therapeutics, Inc. (JNCE) Delisted | Director | 9,713 | $1.88 | $18.3K | $67.9K | 12 | 2022-06-28 |
| AGIO | Chief Operating Officer | 120,834 | $29.46 | $3.56M | -$21.43M | 34 | 2016-01-05 |
Recent Filings
46 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-06-28 | Jounce Therapeutics, Inc. (JNCE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-06-22 | Jounce Therapeutics, Inc. (JNCE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-04-16 | Jounce Therapeutics, Inc. (JNCE) Delisted | Sell (S) | −200 | -$2.0K | EDGAR |
| 2021-03-17 | Jounce Therapeutics, Inc. (JNCE) Delisted | Sell (S) | −200 | -$2.6K | EDGAR |
| 2021-02-18 | Jounce Therapeutics, Inc. (JNCE) Delisted | Sell (S) | −200 | -$2.4K | EDGAR |
| 2021-01-22 | Jounce Therapeutics, Inc. (JNCE) Delisted | Sell (S) | −1,700 | -$20.2K | EDGAR |
| 2020-07-02 | Jounce Therapeutics, Inc. (JNCE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-06-29 | Jounce Therapeutics, Inc. (JNCE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-01-08 | Jounce Therapeutics, Inc. (JNCE) Delisted | Sell (S) | −1,500 | -$12.2K | EDGAR |
| 2019-06-13 | Jounce Therapeutics, Inc. (JNCE) Delisted | Grant (A) | — | $0 | EDGAR |